



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/848,948	05/04/2001	Samir M. Hanash	A31909-PCT USA	8499	
38485	7590 06/06/2005	EXAMINER		INER	
ARENT FOX PLLC			RAWLINGS, STEPHEN L		
1675 BROAD NEW YORK,			ART UNIT	PAPER NUMBER	
			1642		
			DATE MAILED: 06/06/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

## **Advisory Action**

Application No.	Applicant(s)		
09/848,948	HANASH ET AL.		
Examiner	Art Unit		
Stephen L. Rawlings, Ph.D.	1642		

Before the Filing of an Appeal Brief		2 1.7.2.4.					
Before the Filling of all Appeal Brief	Examiner	Art Unit					
	Stephen L. Rawlings, Ph.D.	1642					
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress				
THE REPLY FILED 09 May 2005 FAILS TO PLACE THIS APP	LICATION IN CONDITION FOR A	LLOWANCE.					
this application, applicant must timely file one of the folloplaces the application in condition for allowance; (2) a No	The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of his application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or 3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the ollowing time periods:						
b) The period for reply expires on: (1) the mailing date of this Adv		e final rejection, whicheve	er is later. In no				
event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.  Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).							
Extensions of time may be obtained under 37 CFR 1.136(a). The date on		) and the appropriate exte	ension fee have				
been filed is the date for purposes of determining the period of extension a CFR 1.17(a) is calculated from: (1) the expiration date of the shortened state above, if checked. Any reply received by the Office later than three months earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	atutory period for reply originally set in the	final Office action; or (2)	as set forth in (b)				
2. The Notice of Appeal was filed on A brief in com	pliance with 37 CFR 41.37 must be	e filed within two mon	ths of the date				
of filing the Notice of Appeal (37 CFR 41.37(a)), or any e Since a Notice of Appeal has been filed, any reply must b AMENDMENTS	xtension thereof (37 CFR 41.37(e))	), to avoid dismissal o	of the appeal.				
3. The proposed amendment(s) filed after a final rejection,	but prior to the date of filing a brie	f, will <u>not</u> be entered	because				
(a) They raise new issues that would require further co	nsideration and/or search (see NO	TE below);					
(b) They raise the issue of new matter (see NOTE belo	•						
(c) ☐ They are not deemed to place the application in bet appeal; and/or			the issues for				
(d) They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)).		jected claims.					
4. The amendments are not in compliance with 37 CFR 1.1	21. See attached Notice of Non-Co	ompliant Amendment	i (PTOL-324).				
5. Applicant's reply has overcome the following rejection(s							
<ol> <li>Newly proposed or amended claim(s) would be a the non-allowable claim(s).</li> </ol>							
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed:		ill be entered and an	explanation of				
Claim(s) objected to:							
Claim(s) rejected: <u>1-5,14 and 16-18</u> .							
Claim(s) withdrawn from consideration: <u>6-13 and 19-32</u> .							
AFFIDAVIT OR OTHER EVIDENCE							
<ol> <li>The affidavit or other evidence filed after a final action, be because applicant failed to provide a showing of good an and was not earlier presented. See 37 CFR 1.116(e).</li> </ol>							
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessar	vercome all rejections under appe	al and/or appellant fa	ils to provide a				
10.   The affidavit or other evidence is entered. An explanatio	n of the status of the claims after e	entry is below or attac	ched.				
REQUEST FOR RECONSIDERATION/OTHER		-					
<ol> <li>The request for reconsideration has been considered bu <u>See Continuation Sheet.</u></li> </ol>	t does NOT place the application i	n condition for allowa	ince because:				
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08 or PTO-1449) Paper	No(s). <u>20031010</u>					
13. Other:							
	LARRY R. HELMS, PH.D	M					



Continuation of 5. Applicant's reply has overcome the following rejection(s): The "written description" rejection set forth in section 5 of the preceding Office action; and the rejection under 35 U.S.C. 102(b) in section 7 of the preceding Office action.

Continuation of 11. Although the amendment has been entered, the amendment fails to obviate the remaining rejections of record. Applicant's arguments have been carefully considered but not found persuasive. With regard to the rejections under 35 U.S.C. 102(a) or 103(a) set forth in sections 6 or 9 of the preceding Office action, claim 1, for example, recites the step of detecting at least one S100 protein and the prior art teaches an antibody that binds to the heterodimer of S100-A9 and S100-A8. This antibody is used to detect at least one S100 protein selected from the group consisting of S100-A7 and S100-A8. The prior art teaches that the presence of the S100 protein in a biological sample acquired from a subject detected using the antibody is indicative of lung cancer in the subject. Regarding the rejection set forth in section 8 of the preceding Office action, the prior art, again, teaches an antibody that binds an S100 protein, and claim 14 is drawn to a kit comprising an anti-S100 antibody. Regarding the grounds of rejection set forth in sections 10 and 11, Applicant has again remarked that a terminal disclaimer will be filed; however, as yet, none has been..

ว